AbCheck s.r.o. Receives Grant to Further Develop a Discovery Technology for Functional Antibodies using Microfluidics
October 06 2020 - 6:30AM
Pilsen, Czech Republic, October 6, 2020 -
AbCheck s.r.o., a leader in providing antibody drug discovery,
engineering and optimization services to the biotech and
pharmaceutical industry, today announced that it has been awarded a
grant supporting the further development of a unique approach for
the discovery of functional antibodies using a microfluidic system.
The grant was awarded from the Ministry of Industry and Trade of
the Czech Republic as the managing authority Operational Program,
Enterprise and Innovation for Competitiveness.
The grant, entitled Research and development of
a unique biotechnology for the isolation of antibodies with a
therapeutic effect warrants up to €1.44 million over 3 years and
supports the further development of the microfluidic technology for
the discovery of rare therapeutic antibodies. The technology allows
the screening of droplets containing cells expressing antibodies at
a rate of millions droplets per day. Furthermore, AbCheck will
continue the development of screening assays for direct
functionality selection, e.g. for agonistic antibodies activating a
G protein-coupled receptor (GPCR). The combination of such assays
with the high throughput microfluidic technology allows the
discovery of extremely rare antibodies.
"We are delighted that the Ministry of Industry
and Trade of the Czech Republic has realized the potential of this
novel approach for the discovery of antibodies and subsequently
awarded AbCheck with the grant," stated Volker Lang, Ph.D, Managing
Director of AbCheck.
"We have been developing the microfluidic system
for 2.5 years and have progressed to a stage where we can identify
functional antibodies with very specialized properties,” stated
Oleh Petriv, Ph.D, Head of New Technologies at AbCheck. “This grant
will enable AbCheck to significantly speed up the development of a
differentiated arsenal of bioassays to discover very rare and
unique antibodies for emerging cancer treatments.”
About AbCheck AbCheck s.r.o.
discovers and optimizes human antibodies leveraging several
proprietary platforms including in vitro and in vivo technologies.
We use phage/yeast display libraries (AbSieve®), mass humanization
and antibody optimization (AbAccel®) and a microfluidic platform to
provide high quality leads. Flexibly adapting to our partners’
needs, we offer a variety of business models, including deals
without royalties. AbCheck has proven its capabilities in multiple
partnerships throughout the US and Europe. AbCheck is a wholly
owned subsidiary of Affimed GmbH. For more information, please
visit http://abcheck.eu.
Contact Information:
AbCheckDr. Volker LangManaging
Director+420 378 051500 v.lang@abcheckantibodies.eu
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024